Medicine:GX-19
From HandWiki
Short description: Vaccine candidate against COVID-19
| Vaccine description | |
|---|---|
| Target disease | SARS-CoV-2 |
| Type | DNA vaccination |
| Clinical data | |
| Other names | GX-19N |
| Routes of administration | Intramuscular |
| Identifiers | |
| DrugBank | |
GX-19 is a COVID-19 vaccine candidate developed by Genexine consortium.[1][2][3][4]
It is a DNA-based vaccine that encodes the SARS-CoV-2 spike protein.[5]
References
- ↑ "Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults". United States National Library of Medicine. 24 June 2020. https://clinicaltrials.gov/ct2/show/NCT04445389.
- ↑ Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults. United States National Library of Medicine. 18 January 2021. https://clinicaltrials.gov/ct2/show/NCT04715997. Retrieved 16 March 2021.
- ↑ "S. Korea's Genexine begins human trial of coronavirus vaccine". Reuters. 19 June 2020. https://www.reuters.com/article/health-coronavirus-genexine-vaccine-idUSL4N2DW1T3.
- ↑ "Genexine consortium's Covid-19 vaccine acquires approval for clinical trails in Korea". 11 June 2020. https://www.ivi.int/genexine-consortiums-covid-19-vaccine-acquires-approval-for-clinical-trails-in-korea/.
- ↑ "Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates". Vaccines 9 (4): 307. March 2021. doi:10.3390/vaccines9040307. PMID 33804981.
 |
